Sanofi: Respiratory Syncytial Virus Infections trials
The registry lists 15 Respiratory Syncytial Virus Infections studies with Sanofi as lead sponsor. 0 are open to participants now and 2 have results posted.
Phase 1 13Phase 2 6No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Study on a Live-attenuated Respiratory Syncytial Virus Vaccine for Assessment of Safety, Transmissibility, and Genetic Stability of the Vaccine Virus Among Close Contacts in Infants and Toddlers 6 to < 24 Months of Age in Puerto Rico (USA)CompletedNCT05687279Phase 1/2Results posted
- Study of an Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and ToddlersCompletedNCT04491877Phase 1/2Results posted
- Study of Different Formulations of Vaccines Encoding the RSV Monovalent Antigen or the Flu H5 Antigen in Participants 18 to 49 Years of AgeActive, not recruitingNCT07516418Phase 1
- Study to Evaluate the Safety and Immunogenicity of Investigational Vaccines Using the RSV (Respiratory Syncytial Virus) Monovalent Antigen in Healthy Participants 18 to 49 Years of AgeCompletedNCT07071558Phase 1
- Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and OlderActive, not recruitingNCT06686654Phase 1/2
- Study of a Respiratory Syncytial Virus/Human Metapneumovirus/Parainfluenza Virus Type 3 Vaccine Candidate in Adults Aged 60 Years and OlderCompletedNCT06604767Phase 1
- Study to Evaluate the Safety and Immune Response of an Investigational Vaccine for the Prevention of RSV (Respiratory Syncytial Virus) and (hMPV) Human Metapneumovirus Infection in Participants Aged 60 to 75 YearsCompletedNCT06583031Phase 1
- Study of a Respiratory Syncytial Virus Candidate Formulation in Adults Aged 60 Years and OlderCompletedNCT06251024Phase 2
- Study of the Safety and Immune Response of an Investigational mRNA Vaccine for the Prevention of Respiratory Syncytial Virus and/or Human Metapneumovirus in Participants Aged 18 to 49 Years and 60 Years and OlderCompletedNCT06237296Phase 1
- Study of a Respiratory Syncytial Virus/Human Metapneumovirus Vaccine CandidateCompletedNCT06134648Phase 1/2
- Prospective Surveillance of Respiratory Syncytial Virus Disease in Infants and ToddlersCompletedNCT05964582
- A Multicentre Study in Otherwise Healthy Infants and Toddlers Hospitalised For and Diagnosed With RSV Lower Respiratory Tract Infection to Evaluate the Safety, Tolerability, and Clinical Activity of ALX-0171CompletedNCT02309320Phase 1/2
- ALX-0171 Safety Study in Adults With Hyperresponsive AirwaysCompletedNCT01909843Phase 1
- ALX-0171 Phase I Pharmacokinetic Study in Healthy Male VolunteersCompletedNCT01875926Phase 1
- ALX-0171 Phase I Study, Evaluating Single Ascending Dose and Multiple Dose in Healthy Male VolunteersCompletedNCT01483911Phase 1